Clinical Trials Logo

Lymphoma, Non-Hodgkin clinical trials

View clinical trials related to Lymphoma, Non-Hodgkin.

Filter by:

NCT ID: NCT02593123 Completed - Multiple Myeloma Clinical Trials

Adoptive Immunotherapy in Relapsed Hematological Malignancy: Early GVHD Prophylaxis

Start date: November 4, 2015
Phase: Phase 2
Study type: Interventional

Determine the relapse-free, donor lymphocyte infusion (DLI)-free survival in patients receiving the investigational regimen.This is a randomized phase II clinical trial, comparing two different dosing schedules of mycophenolate mofetil for graft versus host disease (GVHD) prevention following allogeneic stem cell transplantation. Risk for relapse, GVHD and non-relapse mortality will be assessed. Adaptive randomization between two study arms will be performed based on T cell counts at day 60.

NCT ID: NCT02585947 Recruiting - Clinical trials for Non-Hodgkin's Lymphoma, Burkitt's

To Compare the Efficacy of a Prophylactic Use of Tenofovir by Duration for the Non-Hodgkin's Lymphoma

Start date: November 2015
Phase: Phase 4
Study type: Interventional

The objective of this study is to analyze factors affecting Hepatitis B Virus (HBV) reactivation in anti-HBc positive patients with Non-Hodgkin's lymphoma treated with rituximab and compare HBV reactivation rates by duration of prophylactic treatment with tenofovir to contribute to the establishment of an effective prevention strategy.

NCT ID: NCT02581878 Completed - Clinical trials for Lymphoma, Non-Hodgkin

Safety and Tolerability of BAY1862864 Injection in Subjects With Relapsed or Refractory CD22-positive Non-Hodgkin's Lymphoma

Start date: November 20, 2015
Phase: Phase 1
Study type: Interventional

To establish a recommended dose of BAY1862864 Injection and to investigate how the study drug acts in the body, on the cancer cells and how safe it is in patients with advanced non-Hodgkin's lymphoma (NHL)

NCT ID: NCT02581631 Completed - Clinical trials for Non-Hodgkin's Disease

An Investigational Immuno-therapy Safety and Effectiveness Study of Nivolumab in Combination With Brentuximab Vedotin to Treat Non-Hodgkin Lymphomas

CheckMate 436
Start date: February 11, 2016
Phase: Phase 1/Phase 2
Study type: Interventional

The purpose of this study is to determine whether Nivolumab, in combination with brentuximab vedotin, is safe and effective in patients with certain subtypes of non-Hodgkin's lymphomas with CD30 expression that have not responded to treatment or have come back. The subtypes we are studying are Diffuse Large B-Cell Lymphoma (DLBCL), Peripheral T-Cell Lymphoma (PTCL), Cutaneous T-Cell Lymphoma (CTCL), Primary Mediastinal Large B-Cell Lymphoma (PMBL) and Mediastinal Gray Zone Lymphoma (MGZL).

NCT ID: NCT02578511 Withdrawn - Clinical trials for Lymphoblastic Lymphoma in Complete Remission

Standard Maintenance POMP/D Plus Ixazomib Maintenance Therapy in Adult Patients With Acute Lymphoblastic Leukemia, Lymphoblastic Lymphoma or Mixed Phenotype Acute Leukemia in Complete Remission (CR)

Start date: June 29, 2017
Phase: Phase 1
Study type: Interventional

In this phase I study, escalating doses of IXAZOMIB will be combined with the POMP/D regimen.

NCT ID: NCT02576275 Withdrawn - Follicular Lymphoma Clinical Trials

A Study of Duvelisib in Combination With Rituximab and Bendamustine vs Placebo in Combination With Rituximab and Bendamustine in Subjects With Previously-Treated Indolent Non-Hodgkin Lymphoma (BRAVURA)

Start date: December 2015
Phase: Phase 3
Study type: Interventional

This study will evaluate the efficacy and safety of duvelisib in combination with bendamustine and rituximab (DBR) vs placebo in combination with bendamustine and rituximab (PBR) in subjects with previously-treated indolent non-Hodgkin lymphoma (iNHL).

NCT ID: NCT02572453 Terminated - Clinical trials for Recurrent Mantle Cell Lymphoma

Phase 2 Study of AT13387 (Onalespib) in ALK+ ALCL, MCL, and BCL-6+ DLBCL

Start date: April 4, 2016
Phase: Phase 2
Study type: Interventional

This phase II trial studies how well onalespib works in treating patients with anaplastic large cell lymphoma, mantle cell lymphoma, or diffuse large B-cell lymphoma that has not responded to previous treatment (refractory) or that has returned after a period of improvement (recurrent). Onalespib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth.

NCT ID: NCT02568683 Terminated - Clinical trials for Non-Hodgkin Lymphoma

Safety and Efficacy of Entospletinib (ENTO [GS-9973]) Combined With Vincristine (VCR) in Adult Participants With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (NHL)

Start date: February 11, 2016
Phase: Phase 1/Phase 2
Study type: Interventional

The primary objective of this study is to evaluate the safety of ENTO with VCR in participants with relapsed or refractory B-cell NHL.

NCT ID: NCT02568553 Active, not recruiting - Clinical trials for Recurrent Mantle Cell Lymphoma

Lenalidomide and Blinatumomab for the Treatment of Relapsed Non-Hodgkin Lymphoma

Start date: November 15, 2016
Phase: Phase 1
Study type: Interventional

This phase I trial studies the side effects and best dose of lenalidomide and blinatumomab when given together in treating patients with non-Hodgkin lymphoma that has returned after a period of improvement (relapsed). Biological therapies, such as lenalidomide, use substances made from living organisms that may stimulate or suppress the immune system in different ways and stop cancer cells from growing. Blinatumomab is a monoclonal antibody that may interfere with the ability of cancer cells to grow and spread.

NCT ID: NCT02564744 Completed - Clinical trials for Diffuse Large B-Cell Lymphoma

Study to Evaluate the Efficacy and Tolerability of Debio 1562 in Combination With Rituximab in Participants With Relapsed and/or Refractory DLBCL and Other Forms of NHL

Start date: June 5, 2016
Phase: Phase 2
Study type: Interventional

The primary purpose of the study was to determine the safety and tolerability, anti-tumor activity of the proposed Debio 1562 dose regimens in combination with rituximab.